Meibomian Gland Dysfunction Pipeline Analysis & Clinical Trials, 2025, Delveinsight Azura Ophthalmics, Santen Pharmaceutical

(MENAFN- GetNews)


"Meibomian gland dysfunction Pipeline Analysis""DelveInsight's,“Meibomian Gland Dysfunction- Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Meibomian Gland Dysfunction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

According to DelveInsight, the Meibomian Gland Dysfunction pipeline includes 4+ key companies actively engaged in developing 4+ therapeutic candidates for its treatment.

Meibomian gland dysfunction Overview:

Meibomian Gland Dysfunction (MGD) is a long-term ocular disorder in which the eyelid glands produce insufficient oil, destabilizing the tear film and causing dry eye symptoms such as irritation, burning, and blurred vision. The condition often results from gland blockages or thickened secretions, commonly linked to aging, hormonal fluctuations, or associated conditions like rosacea. Diagnosis typically includes evaluating the eyelid margins and tear film, with imaging techniques such as meibography employed to assess gland structure and function.

Download our report @

"Meibomian gland dysfunction Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Meibomian gland dysfunction Therapeutics Market.

Key Takeaways from the Meibomian gland dysfunction Pipeline Report

• DelveInsight's Meibomian Gland Dysfunction (MGD) pipeline report highlights an active landscape with 4+ companies advancing 4+ therapies in development for MGD treatment.

• As of June 2024, Azura Ophthalmics launched a Phase 3 trial (ASTRO study) of AZR-MD-001, a selenium sulfide–based ophthalmic ointment designed to restore gland function by relieving blockages and enhancing meibum quality. The trial will assess its safety and efficacy over 12 months.

• In the same year, the FDA granted 510(k) clearance to the TearCare® System for MGD management.

• Key players such as Azura Ophthalmics, Santen Pharmaceutical, and others are actively evaluating novel therapies, with promising candidates including AZR-MD-001 and additional pipeline drugs.

Meibomian gland dysfunction Pipeline Analysis

The Meibomian gland dysfunction pipeline insig hts report 2025, provides insights into:

• Provides comprehensive insights into key companies developing therapies in the Meibomian gland dysfunction Market.

• Categorizes Meibomian gland dysfunction therapeutic companies by development stage: early, mid, and late-stage.

• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging Meibomian gland dysfunction drugs under development based on:

  • Stage of development

  • Meibomian gland dysfunction Route of administration

  • Target receptor

  • Monotherapy vs. combination therapy

  • Meibomian gland dysfunction Mechanism of action

  • Molecular type

• Offers detailed analysis of:

  • Company-to-company and company-academia collaborations

  • Meibomian gland dysfunction Licensing agreements

  • Funding and investment activities supporting future Meibomian gland dysfunction market advancement.

Request for a sample report @

Meibomian gland dysfunction Emerging Drugs

• AZR-MD-001: Azura Ophthalmics

Azura's lead candidate, AZR-MD-001, is a selenium sulfide–based ointment applied to the lower eyelid for the treatment of Meibomian Gland Dysfunction (MGD). Through blinking, the ointment distributes to the upper lid, where it helps soften gland blockages, decrease abnormal keratin production, and enhance meibum quality. The therapy is currently in Phase III clinical trials evaluating its safety and effectiveness in MGD patients.

Meibomian gland dysfunction Companies

More than four key companies are actively pursuing therapies for Meibomian Gland Dysfunction (MGD), with Azura Ophthalmics at the forefront, advancing a lead candidate now in Phase III clinical trials.

DelveInsight's report covers around 4+ products under different phases of Meibomian gland dysfunction clinical trials like

• Meibomian gland dysfunction Late stage Therapies (Phase III)

• Meibomian gland dysfunction Mid-stage Therapies (Phase II)

• Meibomian gland dysfunction Early-stage Therapies (Phase I)

• Meibomian gland dysfunction Pre-clinical and Meibomian gland dysfunction Discovery stage Therapies

• Meibomian gland dysfunction Discontinued & Inactive Therapies

Meibomian gland dysfunction pipeline report provides the Meibomian gland dysfunction therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Meibomian gland dysfunction Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Meibomian gland dysfunction Therapies and Key Meibomian gland dysfunction Companies: Meibomian gland dysfunction Clinical Trials and recent advancements

Meibomian gland dysfunction Pipeline Therapeutic Assessment

. Meibomian gland dysfunction Assessment by Product Type

. Meibomian gland dysfunction By Stage

. Meibomian gland dysfunction Assessment by Route of Administration

. Meibomian gland dysfunction Assessment by Molecule Type

Download Meibomian gland dysfunction Sample report to know in detail about the Meibomian gland dysfunction treatment market @ Meibomian gland dysfunction Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Meibomian gland dysfunction Current Treatment Patterns

4. Meibomian gland dysfunction - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Meibomian gland dysfunction Late-Stage Products (Phase-III)

7. Meibomian gland dysfunction Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Meibomian gland dysfunction Discontinued Products

13. Meibomian gland dysfunction Product Profiles

14. Meibomian gland dysfunction Key Companies

15. Meibomian gland dysfunction Key Products

16. Dormant and Discontinued Products

17. Meibomian gland dysfunction Unmet Needs

18. Meibomian gland dysfunction Future Perspectives

19. Meibomian gland dysfunction Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Meibomian gland dysfunction Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN10092025003238003268ID1110045981